Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Maria Lavezzi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 31, 2022
The area under the effect curve as an efficacy determinant for anti-infectivesChao Chen, Silvia Maria Lavezzi, Laura Iavarone
Clinical and Translational Science|May 29, 2024
The estimation and translation uncertainties in applying NOAEL to clinical dose escalationChao Chen, Silvia Maria Lavezzi, David McDougall
Journal of Translational Medicine|January 11, 2023
Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paperChao Chen, Xuan Zhou, Silvia Maria Lavezzi, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2018
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issuesSilvia Maria Lavezzi, Enrica Mezzalana, Stefano Zamuner, et al.
Expert Opinion on Drug Discovery|June 10, 2017
Current mathematical models for cancer drug discoveryLetizia Carrara, Silvia Maria Lavezzi, Elisa Borella, et al.
Expert Opinion on Drug Discovery|October 4, 2017
Mathematical modeling of efficacy and safety for anticancer drugs clinical developmentSilvia Maria Lavezzi, Elisa Borella, Letizia Carrara, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 16, 2024
Mechanistic pharmacokinetic-pharmacodynamic modeling and simulations of naloxone auto-injector 10 mg reversal of opioid-induced respiratory depressionTae Eun Yang, Francesca Del Bene, Silvia Maria Lavezzi, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|May 31, 2022
The area under the effect curve as an efficacy determinant for anti-infectivesChao Chen, Silvia Maria Lavezzi, Laura Iavarone
Clinical and Translational Science|May 29, 2024
The estimation and translation uncertainties in applying NOAEL to clinical dose escalationChao Chen, Silvia Maria Lavezzi, David McDougall
Journal of Translational Medicine|January 11, 2023
Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paperChao Chen, Xuan Zhou, Silvia Maria Lavezzi, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2018
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issuesSilvia Maria Lavezzi, Enrica Mezzalana, Stefano Zamuner, et al.
Expert Opinion on Drug Discovery|June 10, 2017
Current mathematical models for cancer drug discoveryLetizia Carrara, Silvia Maria Lavezzi, Elisa Borella, et al.
Expert Opinion on Drug Discovery|October 4, 2017
Mathematical modeling of efficacy and safety for anticancer drugs clinical developmentSilvia Maria Lavezzi, Elisa Borella, Letizia Carrara, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 16, 2024
Mechanistic pharmacokinetic-pharmacodynamic modeling and simulations of naloxone auto-injector 10 mg reversal of opioid-induced respiratory depressionTae Eun Yang, Francesca Del Bene, Silvia Maria Lavezzi, et al.
Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Pageof 1